Cargando…
Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)
Although bevacizumab (Avastin(®)) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors...
Autores principales: | Ko, Jong-Hee, Kwon, Hyuk-Sang, Kim, Bomin, Min, Gihong, Shin, Chorong, Yang, Seok-Woo, Lee, Seong Wook, Lee, Youngmin, Hong, Dahae, Kim, Yong-Sung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356919/ https://www.ncbi.nlm.nih.gov/pubmed/32560565 http://dx.doi.org/10.3390/biom10060919 |
Ejemplares similares
-
Novel Dual-Targeting Antibody Fragment IDB0062 Overcomes Anti–Vascular Endothelial Growth Factor Drug Limitations in Age-Related Macular Degeneration
por: Kim, Seongbeom, et al.
Publicado: (2021) -
Arena-Idb: a platform to build human non-coding RNA interaction networks
por: Bonnici, Vincenzo, et al.
Publicado: (2018) -
Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease
por: Benhadou, Farida, et al.
Publicado: (2020) -
The archaeal RNA chaperone TRAM0076 shapes the transcriptome and optimizes the growth of Methanococcus maripaludis
por: Li, Jie, et al.
Publicado: (2019) -
An Identity-Based (IDB) Broadcast Encryption Scheme with Personalized Messages (BEPM)
por: Xu, Ke, et al.
Publicado: (2015)